CN118434408A - 卡非佐米的稳定即用稀释组合物 - Google Patents

卡非佐米的稳定即用稀释组合物 Download PDF

Info

Publication number
CN118434408A
CN118434408A CN202280084662.4A CN202280084662A CN118434408A CN 118434408 A CN118434408 A CN 118434408A CN 202280084662 A CN202280084662 A CN 202280084662A CN 118434408 A CN118434408 A CN 118434408A
Authority
CN
China
Prior art keywords
component
carfilzomib
pharmaceutically acceptable
injection
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280084662.4A
Other languages
English (en)
Chinese (zh)
Inventor
帕拉斯·拉斯克拉尔·瓦萨纳尼
桑迪普·帕雷什巴·梅塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kashif Bioscience Co ltd
Original Assignee
Kashif Bioscience Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashif Bioscience Co ltd filed Critical Kashif Bioscience Co ltd
Publication of CN118434408A publication Critical patent/CN118434408A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280084662.4A 2021-10-21 2022-10-21 卡非佐米的稳定即用稀释组合物 Pending CN118434408A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121047991 2021-10-21
IN202121047991 2021-10-21
PCT/IB2022/060145 WO2023067569A1 (en) 2021-10-21 2022-10-21 Stable ready to dilute composition of carfilzomib

Publications (1)

Publication Number Publication Date
CN118434408A true CN118434408A (zh) 2024-08-02

Family

ID=86058874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280084662.4A Pending CN118434408A (zh) 2021-10-21 2022-10-21 卡非佐米的稳定即用稀释组合物

Country Status (7)

Country Link
US (2) US12440534B2 (https=)
EP (1) EP4419080A4 (https=)
JP (1) JP2024537910A (https=)
CN (1) CN118434408A (https=)
AU (1) AU2022369145A1 (https=)
CA (1) CA3235911A1 (https=)
WO (1) WO2023067569A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
WO2016185450A1 (en) * 2015-05-21 2016-11-24 Laurus Labs Private Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
WO2018047074A1 (en) * 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10098890B2 (en) * 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
WO2018138557A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Ready-to-use carfilzomib compositions
US20260048003A1 (en) * 2020-01-10 2026-02-19 Amgen Inc. Stable cyclodextrin free carfilzomib formulation
CA3180338A1 (en) * 2020-04-15 2021-10-21 Kashiv Biosciences, Llc Stable ready to dilute formulations of carfilzomib

Also Published As

Publication number Publication date
US20240269224A1 (en) 2024-08-15
WO2023067569A1 (en) 2023-04-27
EP4419080A1 (en) 2024-08-28
AU2022369145A1 (en) 2024-05-23
US20260014226A1 (en) 2026-01-15
JP2024537910A (ja) 2024-10-16
EP4419080A4 (en) 2025-12-24
CA3235911A1 (en) 2023-04-27
US12440534B2 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
US10493079B2 (en) Stable carfilzomib formulations
JP2008543789A (ja) ドセタキセルの液体薬学的処方物
US20100267818A1 (en) Stabilized single-liquid pharmaceutical composition containing docetaxel
AU2009321745B2 (en) Oral dosage forms of bendamustine
US10512654B2 (en) Pharmaceutical composition including dutasteride and capsule formulation comprising the same
US10278946B2 (en) Liquid formulation of cabazitaxel
JP7837563B2 (ja) そのまま安定に希釈するためのカルフィルゾミブ製剤
CN118434408A (zh) 卡非佐米的稳定即用稀释组合物
US20140073670A1 (en) Pharmaceutical composition comprising fexofenadine
JP2011084521A (ja) アゼラスチン塩酸塩含有カプセル剤
US20160120742A1 (en) Compositions including cabazitaxel
US20180243273A1 (en) Composition for Intravesical Administration for Treating Bladder Pain
US20260097042A1 (en) Compound emulsion, preparation method therefor, and use thereof
AU2006257718A1 (en) Liquid pharmaceutical formulations of docetaxel

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination